Invivyd's (IVVD) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Invivyd (NASDAQ:IVVD - Free Report) in a research note published on Monday,Benzinga reports. The brokerage currently has a $9.00 target price on the stock.

IVVD has been the topic of several other reports. HC Wainwright dropped their price objective on shares of Invivyd from $15.00 to $10.00 and set a "buy" rating on the stock in a research note on Wednesday, November 20th. EF Hutton Acquisition Co. I raised shares of Invivyd to a "strong-buy" rating in a report on Wednesday, October 30th. Finally, Morgan Stanley lowered their price objective on Invivyd from $9.50 to $3.55 and set an "overweight" rating on the stock in a report on Wednesday, November 20th. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $7.89.

Invivyd Price Performance

Shares of NASDAQ:IVVD traded down $0.06 during trading on Monday, reaching $0.41. The company had a trading volume of 1,317,696 shares, compared to its average volume of 1,920,166. Invivyd has a fifty-two week low of $0.38 and a fifty-two week high of $5.20. The stock's fifty day moving average price is $0.54 and its 200 day moving average price is $0.86. The firm has a market capitalization of $49.31 million, a price-to-earnings ratio of -0.21 and a beta of 0.64.

Insider Buying and Selling

In related news, Director Terrance Mcguire sold 160,400 shares of the firm's stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $0.59, for a total value of $94,636.00. Following the completion of the transaction, the director now directly owns 4,202,679 shares of the company's stock, valued at $2,479,580.61. This trade represents a 3.68 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last 90 days, insiders have sold 816,466 shares of company stock valued at $423,214. Corporate insiders own 17.90% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Proficio Capital Partners LLC acquired a new position in shares of Invivyd during the 3rd quarter worth approximately $27,000. XTX Topco Ltd raised its holdings in shares of Invivyd by 68.1% in the second quarter. XTX Topco Ltd now owns 37,938 shares of the company's stock worth $42,000 after acquiring an additional 15,376 shares during the last quarter. Rhumbline Advisers lifted its position in shares of Invivyd by 4,434.1% in the second quarter. Rhumbline Advisers now owns 84,017 shares of the company's stock valued at $92,000 after acquiring an additional 82,164 shares in the last quarter. Susquehanna Fundamental Investments LLC acquired a new position in Invivyd in the 2nd quarter valued at about $115,000. Finally, Barclays PLC lifted its holdings in Invivyd by 179.6% in the 3rd quarter. Barclays PLC now owns 117,973 shares of the company's stock valued at $120,000 after purchasing an additional 75,780 shares in the last quarter. Hedge funds and other institutional investors own 70.36% of the company's stock.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.